In conclusion, a pleiotropic oncogenic role for TROP2 has been identified in HNSCC, in which its over-expression promotes tumor progression and associates with patient survival by regulating AKT and ERK/MAPK signaling pathways. The gene discussed is TACSTD2; the disease is neoplasm.